Aragen Launches CHOMax™, an Accelerated Platform for DNA to IND-Enabling Clinical Supply in ~10 MonthsAccelerated pathway: ...

Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.

Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026Five additional Phase 3 ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product ...

Asia-Pacific's penicillin G acylase market surges on China's Shandong mega-scale (60% global 6-APA) and India's PLI ramps ...

Damaged cells produce molecules that trigger inflammation and stimulate the innate or adaptive immune response. These damage-associated molecular patterns, or DAMPs, may be released in response to ...